Andy Darlington: Randomized Evidence for Catheter-Based Treatment of Intermediate-High-Risk PE
Andy Darlington, Global Partnerships Manager of Medical Devices at Radcliffe Group, shared a post on LinkedIn:
“In this clip, Prof Lukas Hobohm reviews the findings from the HI-PEITHO randomised controlled trial.
The trial compared EKOS plus anticoagulation with anticoagulation alone in 544 patients with intermediate-high-risk PE, assessing whether intervention could reduce early PE-related complications.
The discussion explores the reduction in the composite outcome of PE-related mortality, cardiopulmonary decompensation or PE recurrence within seven days, alongside findings on major bleeding and hospital length of stay.
Watch the clip below for insights into how randomised evidence is shaping treatment strategies for intermediate-high-risk PE.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 14:31Yaozhi Wang: AI Increased Incidental Pulmonary Embolism Detection
-
Sep 15, 2026, 14:30Moe Alsumidaie: Mitapivat Challenges the Transfusion-Centric Model of Thalassaemia Care
-
Sep 15, 2026, 14:28Jonathan Douxfils: The Emerging Role of Estetrol in Menopausal Hormone Therapy
-
Sep 15, 2026, 14:19Mohammad Salar Amoli: The Coagulation Laboratory Approach to Hemophilia A
-
Sep 15, 2026, 14:09Lydia Pecker: A Call for Blood Donors for Sickle Cell Patients
-
Sep 15, 2026, 13:50Richard Godin: Challenges in Diagnosing Homozygous Familial Hypercholesterolemia
-
Sep 15, 2026, 13:42Sujan Sivasubramaniyam: Three Decades of Progress for Children with Haemophilia in Morocco
-
Sep 15, 2026, 13:31Mohammed Alkhani: Challenging the Conventional Approach to Paget-Schroetter Syndrome
-
Sep 15, 2026, 13:29Shadi Tabibian: Three Years of Progress Toward Life Beyond Hemophilia